The latest price target for Kairos Pharma (AMEX:KAPA) was reported by D. Boral Capital on November 14, 2024. The analyst firm set a price target for $9.00 expecting KAPA to rise to within 12 months (a possible 473.25% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Kairos Pharma (AMEX:KAPA) was provided by D. Boral Capital, and Kairos Pharma maintained their buy rating.

There is no last upgrade for Kairos Pharma

There is no last downgrade for Kairos Pharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kairos Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kairos Pharma was filed on November 14, 2024 so you should expect the next rating to be made available sometime around November 14, 2025.

While ratings are subjective and will change, the latest Kairos Pharma (KAPA) rating was a maintained with a price target of $9.00 to $9.00. The current price Kairos Pharma (KAPA) is trading at is $1.57, which is out of the analyst’s predicted range.